Prostate cancer is often discussed as a “men’s health” issue. That label may be convenient for a clinic brochure, but it is not medically precise. Transgender women, nonbinary people, gender-diverse people, and some transgender men may have a prostate and therefore may develop prostate cancer.
The simplest rule is also the most useful: cancer screening should follow the organs a person has, not the gender marker printed on an insurance card. The prostate, after all, does not check someone’s pronouns before developing a medical problem.
Unfortunately, prostate cancer research and screening recommendations have historically focused almost entirely on cisgender men. As a result, trans and nonbinary patients may encounter confusing terminology, uncertain PSA thresholds, missed screening conversations, or clinicians who incorrectly assume that gender-affirming surgery removed the prostate. Understanding the anatomy, risks, symptoms, tests, and treatment considerations can make care safer and far less awkward.
Which Trans and Nonbinary People Can Develop Prostate Cancer?
Anyone who has a prostate can potentially develop prostate cancer, regardless of gender identity. The prostate is usually present in people who were assigned male at birth. A person with this anatomy may identify as a woman, a man, nonbinary, agender, gender-fluid, or another gender.
Most people assigned female at birth do not have a prostate and do not need conventional prostate cancer screening. Because gender identity alone does not reveal someone’s organs or surgical history, healthcare professionals should use an individualized anatomical inventory rather than making assumptions.
Does gender-affirming surgery remove the prostate?
Usually, no. Procedures such as vaginoplasty, vulvoplasty, orchiectomy, and penectomy generally leave the prostate in place. Removing a healthy prostate during gender-affirming genital surgery could add considerable risks involving the urinary tract, nerves, rectum, and nearby tissues. Therefore, a trans woman or nonbinary person may still have a prostate after extensive genital surgery.
An orchiectomy removes the testicles, which produce most of the body’s testosterone, but it does not remove the prostate. Lower testosterone may shrink the gland and alter cancer risk, yet the remaining prostate tissue can still develop cancer.
How Common Is Prostate Cancer in Transgender People?
The honest answer is that researchers do not yet know precisely. Large cancer registries have not always recorded gender identity, sex assigned at birth, hormone history, or gender-affirming procedures consistently. Some patients may also be incorrectly categorized in medical databases. That makes reliable population-level estimates difficult.
A large study using U.S. Veterans Health Administration data estimated approximately 14 prostate cancer cases per year for every 10,000 transgender women, compared with about 33 cases per 10,000 cisgender men. This suggests that the rate may be lower among transgender women, particularly those using estrogen, but it does not mean the risk is zero.
The study population was relatively small and consisted largely of older White veterans, so the results may not represent every trans community. Lower recorded incidence might also partly reflect fewer screening conversations, suppressed PSA results, missed diagnoses, or incomplete gender data.
In other words, “less common” should not become “impossible.” Medicine has enough plot twists without adding that one.
How Gender-Affirming Hormones Affect the Prostate
Many transfeminine and nonbinary people use estrogen, testosterone-blocking medication, or both. These treatments often reduce testosterone levels, decrease prostate volume, and lower prostate-specific antigen, commonly called PSA.
Because many prostate cancers are stimulated by androgens such as testosterone, long-term testosterone suppression may reduce the likelihood that some cancers will develop or grow. Orchiectomy may produce a similar androgen-lowering effect. However, researchers have not established exactly how much protection these treatments provide or whether the effect changes according to age, medication, dosage, and duration of treatment.
Prostate cancer can also be present before a person starts gender-affirming hormone therapy. Several reported cases have involved people who began estrogen later in life, meaning an undetected tumor may already have existed.
Estrogen can make PSA harder to interpret
PSA is a protein produced by prostate tissue. A PSA blood test can help identify people who may need additional evaluation, although it cannot diagnose cancer by itself.
A 2024 study of transgender women receiving estrogen found a median PSA level of only 0.02 nanograms per milliliter. More than one-third had an undetectable PSA. For comparison, PSA values are generally much higher in similarly aged cisgender men without known prostate cancer.
This creates an important problem: a PSA value that appears reassuring under traditional reference ranges might be unusual for someone whose PSA has been strongly suppressed by estrogen. The historically familiar threshold of 4.0 nanograms per milliliter may be far too high for a person receiving feminizing hormones.
There is currently no universally accepted PSA cutoff specifically validated for transgender women or nonbinary people using estrogen. Clinicians may need to consider changes from the patient’s personal baseline, hormone history, testosterone level, symptoms, family history, examination findings, and imaging rather than relying on one generic number.
Prostate Cancer Risk Factors
Gender identity does not erase the major biological and hereditary risk factors associated with prostate cancer. Important considerations include:
- Age: Risk rises substantially with age, especially after 50.
- Black ancestry: U.S. data show higher rates of prostate cancer, earlier diagnosis, aggressive disease, and prostate cancer death among Black populations.
- Family history: Risk is higher when a parent, sibling, or child has had prostate cancer, especially if the cancer developed at a younger age or became metastatic.
- Inherited genetic variants: Variants involving BRCA2, BRCA1, HOXB13, and certain DNA-repair genes may increase risk.
- Previous hormone exposure: The age at which estrogen or androgen suppression began may influence risk, although current research remains limited.
- Personal medical history: Overall health, prostate conditions, medications, and prior pelvic treatment can affect screening and diagnosis.
Trans and nonbinary people may face an additional nonbiological risk: delayed care. Previous discrimination, misgendering, cost concerns, lack of insurance coverage, uncomfortable examinations, and clinicians unfamiliar with transgender health can discourage routine visits. A cancer does not become less serious simply because the appointment system is having an identity crisis.
Should Trans and Nonbinary People Get PSA Screening?
There is no single screening schedule that is appropriate for every person with a prostate. Even in cisgender populations, major organizations emphasize shared decision-making because PSA screening offers possible benefits as well as harms.
The U.S. Preventive Services Task Force recommends an individual discussion about PSA screening for adults ages 55 to 69 within the population covered by its guidance. It recommends against routine screening after age 70. The American Cancer Society suggests discussing screening at age 50 for people at average risk and at age 45 for those at higher risk, including Black people and people with a close relative diagnosed at a younger age.
These recommendations were largely developed from studies involving cisgender men. They should not simply be copied and pasted onto every transgender patient without considering hormone use, surgical history, individual risk, life expectancy, and personal preferences.
Questions to discuss with a healthcare professional
- Do I currently have a prostate?
- At what age did I begin estrogen or testosterone suppression?
- What medications could lower my PSA?
- Do I have a previous PSA result that can serve as a baseline?
- Does my family have a history of prostate, breast, ovarian, pancreatic, or related hereditary cancers?
- Could genetic counseling be appropriate?
- What would happen if my PSA result were abnormal?
- How might testing or treatment affect my gender-affirming care?
Screening should be a conversation, not an ambush involving a laboratory form and no explanation.
Symptoms That Should Not Be Ignored
Early prostate cancer often causes no symptoms. That is one reason screening is considered for some people. When symptoms do occur, they can overlap with benign prostate enlargement, infection, medication effects, pelvic-floor conditions, or complications unrelated to cancer.
Possible warning signs include:
- Difficulty starting urination
- A weak or interrupted urine stream
- Needing to urinate more frequently, especially at night
- Pain or burning during urination
- Blood in urine or ejaculatory fluid
- New pelvic, hip, back, or rib pain
- Unexplained weight loss or persistent fatigue
- Leg weakness, numbness, or loss of bladder or bowel control
Urinary symptoms are more commonly caused by noncancerous conditions, but they still deserve medical evaluation. Sudden leg weakness, numbness, or loss of bladder or bowel control requires urgent care because it can indicate pressure on the spinal cord.
People who have undergone vaginoplasty should also report unexplained pelvic pain, bleeding, urinary changes, painful dilation, or new discomfort involving the neovagina. These symptoms do not automatically mean prostate cancer, but surgical anatomy can change how prostate or pelvic conditions are noticed.
How Prostate Cancer Is Diagnosed
Evaluation may begin with medical history, medication review, PSA testing, and a physical examination. The clinician should know about current and previous hormone therapy, orchiectomy, vaginoplasty, pelvic procedures, and any medications that may suppress PSA.
Physical examination
A digital rectal examination may allow a clinician to feel part of the prostate for hard or irregular areas. After vaginoplasty, examination through the neovagina may sometimes provide another route to assess nearby tissues, depending on the surgical technique and the patient’s anatomy. Any examination should be explained beforehand, performed only with consent, and stopped when requested.
MRI, biomarkers, and biopsy
If PSA trends, symptoms, or examination findings are concerning, clinicians may use prostate MRI, repeat PSA testing, additional blood or urine biomarkers, or a risk calculator. A biopsy is generally required to confirm prostate cancer.
Previous genital surgery may influence the safest biopsy route. Urologists and radiologists should review operative records when available rather than treating the pelvis like a surprise package. Transperineal, transrectal, or other image-guided approaches may be considered according to individual anatomy.
Treatment Options and Gender-Affirming Care
The main treatment options are broadly similar for anyone with prostate cancer. Depending on the tumor’s grade, stage, genetic features, and expected behavior, care may include:
- Active surveillance for selected low-risk cancers
- Surgical removal of the prostate
- External-beam radiation therapy
- Brachytherapy
- Androgen-deprivation therapy
- Newer hormone-targeting medicines
- Chemotherapy, immunotherapy, or targeted treatment for advanced disease
Treatment planning may be more complex after genital reconstruction. Prostate surgery can affect urinary control, pelvic nerves, sexual sensation, and nearby reconstructed tissues. Radiation may affect the bladder, rectum, pelvic skin, neovagina, scar tissue, and comfort with dilation. These possibilities should be discussed with clinicians experienced in both prostate cancer and gender-affirming anatomy.
Does estrogen have to be stopped?
A prostate cancer diagnosis does not automatically require every patient to permanently stop estrogen. The decision depends on the cancer’s biology, treatment plan, hormone levels, cardiovascular and bone health, and the importance of hormone therapy to the patient’s well-being.
Some prostate cancer treatments intentionally lower androgen activity further. An oncologist, urologist, and hormone-prescribing clinician should coordinate care rather than giving contradictory instructions from three separate corners of the hospital.
Changes to gender-affirming hormone therapy can cause distress, hot flashes, mood changes, body changes, fatigue, and concern about losing progress made during transition. These effects deserve the same attention as other treatment-related quality-of-life issues.
Building a Gender-Affirming Cancer Care Plan
Respectful prostate cancer care involves more than using the correct name, although that is a good place to start. A supportive clinical team should:
- Record the patient’s name, pronouns, anatomy, and preferred terminology accurately.
- Ask which words the patient prefers for body parts.
- Explain why sensitive questions and examinations are medically relevant.
- Avoid unnecessary exposure during examinations and procedures.
- Discuss fertility, sexual function, continence, sensation, and gender goals without assumptions.
- Coordinate oncology treatment with hormone management.
- Recognize the effects of racism, disability, poverty, immigration status, and anti-trans discrimination.
- Offer mental health, social work, navigation, and peer-support resources when available.
Patients may also ask to bring a trusted support person, request a clinician experienced in transgender health, or ask that examinations be divided across visits. Consent is not a one-time checkbox; it is an ongoing conversation.
Experiences Related to Prostate Cancer in Trans and Nonbinary People
The following scenarios are composites created from themes commonly described in transgender healthcare and cancer research. They are not biographies of specific patients.
Experience 1: The screening conversation that never happened
Jordan, a 58-year-old nonbinary person, had attended the same primary care office for years. The electronic record listed a nonbinary gender identity, but no one had documented Jordan’s organs or previous procedures. Every annual visit included cholesterol, blood pressure, and colon cancer reminders. Prostate screening was never mentioned because the automated system only sent prompts to patients categorized as male.
During an appointment for nighttime urination, a new clinician asked a simple question: “Do you have a prostate?” Jordan did. The clinician reviewed the benefits and limitations of PSA testing, explained how Jordan’s estrogen and antiandrogen medication could lower the result, and ordered a baseline test. The most meaningful part of the visit was not the blood draw. It was finally having a provider who understood that gender identity and anatomy belong in the same chart without being treated as the same thing.
Experience 2: A “normal” PSA that needed a second look
Marisol, a transgender woman in her early sixties, had used estrogen for more than 15 years and had undergone vaginoplasty. She developed persistent pelvic discomfort and urinary changes. Her PSA was well below the traditional threshold commonly used in cisgender men, so the first clinician dismissed prostate cancer as unlikely.
A urologist familiar with transfeminine care noticed that the value was substantially higher than Marisol’s previous PSA and unusual for someone with long-term testosterone suppression. An MRI identified a suspicious area, and further testing confirmed cancer.
Marisol’s experience illustrates why a laboratory result cannot be separated from hormone history. The number was not dramatically high according to a generic reference range, but the change from her personal baseline mattered. “Normal” is not a magic spell that makes symptoms disappear.
Experience 3: Protecting gender goals during treatment
Alex, a transfeminine nonbinary adult, was diagnosed with localized prostate cancer. The first specialist discussed surgery and urinary side effects but never mentioned Alex’s estrogen treatment, sexual goals, or plans for future genital surgery. Alex left the consultation feeling as though the cancer team had replaced a whole person with a prostate-shaped diagram.
A second multidisciplinary team included a urologic oncologist, radiation oncologist, endocrinologist, and gender-affirming surgeon. Together they discussed cancer control, hormone management, urinary function, potential effects on later surgery, and the language Alex wanted clinicians to use.
The final treatment decision was medically appropriate and personally acceptable. Alex still experienced anxiety and side effects, but the process felt collaborative rather than coercive. Good cancer care did not require choosing between survival and identity.
Experience 4: Survivorship beyond the final treatment
Denise, a transgender woman treated for prostate cancer, expected follow-up visits to focus on PSA tests and scans. She was less prepared for fatigue, urinary leakage, reduced sexual sensation, body-image concerns, and anxiety before every laboratory result.
A survivorship clinic helped coordinate pelvic-floor therapy, hormone monitoring, counseling, and practical continence support. Staff used Denise’s chosen name and did not repeatedly ask unrelated questions about her transition. That may sound basic, but basic dignity can feel revolutionary after years of defensive healthcare encounters.
Her experience also showed that survivorship is not merely the period after cancer treatment. It includes rebuilding confidence, intimacy, daily routines, and trust in one’s body. For trans and nonbinary survivors, it may additionally involve protecting gender affirmation while adapting to permanent changes caused by cancer or its treatment.
Conclusion
Prostate cancer can affect transgender women, nonbinary people, and anyone else who has a prostate. Gender-affirming surgery usually does not remove the gland, while estrogen and androgen-blocking treatment may lower both prostate cancer risk and PSA levels. That combination can make screening decisions more complicatednot less important.
Patients and clinicians should use an anatomy-based, risk-aware approach that accounts for age, ancestry, family history, genetic risk, symptoms, hormone use, surgical history, and personal priorities. Because trans-specific screening thresholds remain uncertain, PSA trends and individual baselines may sometimes provide more useful context than a standard cutoff alone.
Most importantly, no one should have to trade respectful care for competent care. The goal is both: evidence-based cancer prevention delivered by professionals who recognize the whole person attached to the prostate.
Note: This article is intended for general education and cannot replace individualized medical advice. Anyone with concerning urinary, pelvic, neurological, or unexplained systemic symptoms should speak with a qualified healthcare professional.
